NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
BlossomHill Therapeutics
Novartis
Baylor College of Medicine
University of Chicago
Seagen Inc.